Cargando…
The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
The genomics-based molecular classifications aim at identifying more homogeneous classes than immunohistochemistry, associated with a more uniform clinical outcome. We conducted an in silico analysis on a meta-dataset including gene expression data from 5342 clinically defined ER+/HER2− breast cance...
Autores principales: | Bertucci, François, Finetti, Pascal, Goncalves, Anthony, Birnbaum, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060267/ https://www.ncbi.nlm.nih.gov/pubmed/32195331 http://dx.doi.org/10.1038/s41523-020-0151-5 |
Ejemplares similares
-
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Goncalves, Anthony, et al.
Publicado: (2021) -
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
por: Bertucci, F, et al.
Publicado: (2012) -
XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016) -
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023) -
Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)